Repurposed Drugs Show Promise for Aggressive Infant

What Is MLL-Rearranged Infant Leukemia?

MLL-rearranged acute lymphoblastic leukemia, also called KMT2A-rearranged ALL, is one of the most challenging pediatric cancers physicians face. Unlike most childhood leukemias, which respond well to standard chemotherapy and have cure rates above 90 percent, infant leukemia carries a much poorer prognosis. The disease is biologically distinct, characterized by a chromosomal translocation involving the KMT2A gene on chromosome 11, which disrupts normal blood cell development and drives rapid leukemic growth.

Babies diagnosed in their first year of life face the worst outcomes, with long-term survival hovering around 50 percent despite the use of intensive multi-agent chemotherapy and stem cell transplantation. Treatment is further complicated by the vulnerability of infant patients, whose developing organs and immune systems are highly sensitive to the toxic side effects of conventional cytotoxic therapy. This has driven researchers to seek targeted therapies that can be both more effective and less harmful.

How Could Repurposed Drugs Improve Outcomes?

Drug repurposing is a strategy that takes medications already approved for other diseases and tests them against new targets, dramatically shortening the path from discovery to clinical use. The HemaSphere study screened clinically available compounds against MLL-rearranged leukemia cells and identified three candidates that showed strong activity, including effects on signaling pathways that the leukemia depends on for survival. Because these drugs already have established safety profiles in humans, they can move into pediatric trials more quickly than entirely new molecules.

For infant leukemia in particular, the appeal of repurposed drugs is twofold. First, they may achieve better disease control by hitting the molecular drivers of MLL-rearranged ALL more precisely than broad chemotherapy. Second, by reducing reliance on highly toxic regimens, they could spare developing infants from long-term complications such as neurocognitive deficits, growth impairment, and secondary cancers. The next steps will involve carefully designed clinical trials to confirm safety and efficacy in this fragile patient population.

What Does This Mean for Pediatric Cancer Care?

The findings are part of a broader shift in pediatric oncology toward precision medicine, where treatments are matched to the specific molecular features of a child's cancer rather than applied as one-size-fits-all chemotherapy. International collaborations such as the Interfant trials have made steady progress in standardizing care for infant leukemia, but survival improvements have plateaued in recent decades. New therapeutic options are urgently needed.

If the repurposed drugs identified in this study prove successful in clinical trials, they could be integrated into existing treatment protocols relatively quickly. The work also highlights the value of academic-industry collaboration in tackling rare diseases that often receive limited commercial investment. For families facing an infant leukemia diagnosis, the prospect of more effective and less toxic treatment represents a meaningful step forward.